Cleveland Clinic Abu Dhabi Launches First Continuous Infusion Therapy For Parkinson's Disease In GCC Region

Cleveland Clinic Abu Dhabi, part of the M42 group, has introduced continuous infusion therapy for advanced Parkinson’s disease. This makes it the first hospital in the GCC to offer this treatment. The therapy provides an alternative for patients who are not candidates for deep brain stimulation (DBS) or prefer a non-invasive option. It is available to all patients in advanced stages of Parkinson’s.

The infusion system works like an insulin pump, delivering a steady supply of levodopa-carbidopa through a small device attached to the skin. This method ensures consistent medication levels, reducing motor fluctuations and dyskinesias. Unlike oral medications, which can cause inconsistent symptom control due to fluctuating absorption, this approach offers stable management around the clock.

Since 2019, Cleveland Clinic Abu Dhabi has been at the forefront of advanced Parkinson’s treatments in the UAE. The hospital has performed over 100 DBS surgeries since its introduction. Now, with continuous infusion therapy, they expand their offerings to include a full spectrum of treatments tailored to individual patient needs.

Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, emphasised the importance of this advancement: "The introduction of continuous therapy in the UAE and GCC represents a critical advancement in how we approach patient care and outcomes in the region. As neurodegenerative diseases become more prevalent, patients are increasingly in need of personalised, innovative solutions."

The hospital ensures comprehensive care with a team of specialists providing 24/7 support. This includes dedicated rehabilitation professionals and other medical experts who work together to deliver patient-centred care. Follow-up visits post-treatment are reduced to once every six months compared to frequent monitoring required after DBS surgery.

Dr. Shivam Om Mittal from Cleveland Clinic Abu Dhabi led the treatment initiative. He stated: "We are proud to be the first in the region to offer this groundbreaking therapy so soon after its global introduction. At Cleveland Clinic Abu Dhabi, we provide a full spectrum of advanced Parkinson’s treatments—including oral medication, deep brain stimulation (DBS), and now this treatment, ensuring each patient receives a personalised care plan."

Impact on Patient Lives

This innovation is changing how advanced Parkinson’s disease is managed by offering greater stability and independence for patients. Its simple design allows easy implementation for both patients and caregivers. With Parkinson’s being the fastest-growing neurodegenerative condition globally—expected to double by 2040—the need for effective treatments is urgent.

Currently affecting 1% of individuals over 60 worldwide, there is also an increase in young-onset cases under 50 years old being diagnosed. Cleveland Clinic Abu Dhabi continues to lead neurological care advancements through pioneering therapies like continuous infusion therapy.

The hospital's multidisciplinary approach integrates neurology, surgery, rehabilitation, and other specialties seamlessly. This commitment sets new standards in improving treatment options that transform patient outcomes across the region.

With inputs from WAM